Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ENDRA Life SciencesNDRA -1.92%29 Return-on-Tangible-Asset is -367.87% as of Mar. 2026. GuruFocus rates NDRA with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, ENDRA Life Sciences ranks worse than 98.12% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. ENDRA Life Sciences's annualizedNet Income for the quarter that ended in Mar. 2026 was $-5.24 Mil. ENDRA Life Sciences's average total tangible assets for the quarter that ended in Mar. 2026 was $1.43 Mil. Therefore, ENDRA Life Sciences's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -367.87%.
The historical rank and industry rank for ENDRA Life Sciences's Return-on-Tangible-Asset or its related term are showing as below:
NDRA'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -567.48 Med: -154.85 Max: -103.8
Current: -338.24
During the past 12 years, ENDRA Life Sciences's highest Return-on-Tangible-Asset was -103.80%. The lowest was -567.48%. And the median was -154.85%.
NDRA's Return-on-Tangible-Asset is ranked worse than 98.12% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.4
vs NDRA: -338.24
ENDRA Life Sciences (NAS:NDRA) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
ENDRA Life Sciences Return-on-Tangible-Asset Related Terms
ENDRA Life Sciences Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for ENDRA Life Sciences's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ENDRA Life Sciences Return-on-Tangible-Asset Chart
NDRA vs BIAF, ADVB, MBAI: Return-on-Tangible-Asset Comparison
For the Diagnostics & Research subindustry, ENDRA Life Sciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ENDRA Life Sciences Return-on-Tangible-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ENDRA Life Sciences's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where ENDRA Life Sciences's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -367.87% mean?
ENDRA Life Sciences (NDRA) has a Return-on-Tangible-Asset of -367.87% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on ENDRA Life Sciences and its competitors. According to the industry distribution chart, ENDRA Life Sciences ranks #209 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 98.1%.
Is ENDRA Life Sciences' Return-on-Tangible-Asset too high?
ENDRA Life Sciences' current Return-on-Tangible-Asset is -367.87%. Based on the distribution chart, ENDRA Life Sciences ranks #209 out of 213 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, ENDRA Life Sciences has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does ENDRA Life Sciences' Return-on-Tangible-Asset compare to BIAF and ADVB?
According to the Medical Diagnostics & Research industry distribution chart, ENDRA Life Sciences ranks #209 out of 213 companies for Return-on-Tangible-Asset. This places ENDRA Life Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Asset depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on ENDRA Life Sciences and its competitors. ENDRA Life Sciences's current Return-on-Tangible-Asset is -367.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ENDRA Life Sciences stock overvalued right now?
ENDRA Life Sciences (NDRA) has a current Return-on-Tangible-Asset of -367.87%. The current Return-on-Tangible-Asset is -367.87%. ENDRA Life Sciences' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For ENDRA Life Sciences (NDRA), the current Return-on-Tangible-Asset is -367.87% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ENDRA Life Sciences Inc is engaged in the development of thermo-acoustic enhanced ultrasound (TAEUS) technology to improve the capabilities of clinical diagnostic ultrasound. The company's technology is used to measure tissue composition, including the assessment of fat in the liver, and is being developed for additional clinical applications such as tissue temperature monitoring.
29GF Score
Get the complete analysis for NDRA
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NDRA has been successfully added to your 
